Tax Season is Here! Save 15% on H&R Block Online
iconAll times are GMT -4. The time now is 04:29 AM. | Search:

» StockRants Stock Forum » Public Stock Forums » US Stock Picks » Strong Buy: AEZS (MC $67 M) (Cash $45.7M ) FDA Decision on Nov 5= 300% Potential !



Reply
 
Thread Tools Search this Thread
Old 07-01-2014, 12:10 PM   Nav to Top  #1
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 298
Favorites: Aapl celg onxx
Rep Power: 116
Reputation: 36
Biohero is on a distinguished road
Default AEZS (MC $67 M) (Cash $45.7M ) FDA Decision on Nov 5= 300% Potential !

This Stock is one of the cheapest in the Biotech Sector . They have $45.7 M in Cash and a Market Cap of just $67 M thats ridiculous for a Company with such a Mega Pipeline .Another good sign is that Management bought 187k Shares in last few weeks .This is the Perfect time to load up before the speculators jumping in .
FDA decision on November 5 (Macrilen) and Interim Phase 3 results in 1H 2015 (ZoptEC) !
AEZS could run to $3-5 before FDA decision in early November .GL
Aeterna Zentaris (AEZS)

Market Cap: $67 M
Cash: $45.7 M
Price: $1.18

Shares Out: 56.5 M


Insider activity:
AEZ Latest Filings | Canadian Insider
Jun 10/14 Jun 10/14 Egbert, Carolyn Direct Ownership Common Shares 10 - Acquisition in the public market 100,000 $1.10 USD
Apr 14/14 Apr 11/14 Dodd, David Alan Direct Ownership Common Shares 10 - Acquisition in the public market 87,000 $1.15 USD

Pipeline
?terna Zentaris Inc: Products on the Market


New Presentation
http://www.aezsinc.com/pdfdyn/AEZS%2...une%202014.pdf



MACRILEN™(macimorelin)

•Filing of a New Drug Application ("NDA") seeking approval for the commercialization of MACRILEN™ as the firstavailable oral product indicated for the evaluation of Adult Growth Hormone Deficiency


. NDA currently undersubstantive review by the US Food and Drug
Administration with a Prescription Drug User Fee Act date of November 5,2014


Zoptarelin doxorubicin

Operate trial in support of achieving first interim analysis for
ZoptEC Phase 3 trial in H1-2015
Biohero is offline   0 thumbs up / 1 thumbs down. Rate this post Yes | No Reply With Quote
Old 08-15-2014, 08:42 AM   Nav to Top  #2
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 298
Favorites: Aapl celg onxx
Rep Power: 116
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

Still a great entry point at this ridiculous low price ...

Buy rating and a 12-month price target of $3.00 per share

In a report released Thursday, H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage on AEterna Zentaris (NASDAQ: AEZS) with a Buy rating and a 12-month price target of $3.00 per share.

Analysts at H.C. Wainwright favor AEterna for the likelihood of its drug Macrilen passing its FDA review. Macrilen is an Adult Growth Hormone Deficiency (AGHD) detection treatment, expected to be approved by the PDUFA date of November 25 and acquired in-licenses approved the treatment expected by the end of 2014.

The Wainwright note also focused on Zoptarelin doxorubicin, with most sourced guidance anticipating its release in 2018. Zoptarelin is a high-purpose endometrial cancer treatment, with expected high growth into AEterna's share price over time.
Biohero is offline   0 thumbs up / 1 thumbs down. Rate this post Yes | No Reply With Quote
Old 08-28-2014, 10:19 AM   Nav to Top  #3
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 298
Favorites: Aapl celg onxx
Rep Power: 116
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

AEZS runnning higher guys
PDUFA date on November 5

Market Cap just $75 M
Cash : $40 M

Cheapest FDA play out there for 2014

Buy rating on Aeterna Zentaris (AEZS) with a Buy rating and a $5 price target !!!

In a research report issued Friday, Maxim Group analyst Jason Kolbert maintained a Buy rating on Aeterna Zentaris (AEZS) with a Buy rating and a $5 price target, which represents a potential upside of 400% from where the stock is currently trading. The report follows the company’s second-quarter update, which was released last week.

Kolbert noted, “Aetrena Zentaris reported the quarter. The company had an operating loss of $5M and finished the year with just under $40M in cash. We believe management is executing a productive turnaround of the business. The launch of Macrilen should happen in early 2015 and we are hopeful to see this product build traction over time in the traumatic brain injury marketplace. We extend our model to 2020 and assume clinical success with AEZS in endometrial cancer (US & EU).” Furthermore, the analyst noted, “The New Drug Application (NDA) for Macrilen is submitted (11.5.2014 PDUFA) and the review process is now underway. The phase 3 data demonstrated that the compound has the potential to become the first orally approved diagnostic test for AGHD, with accuracy comparable to available testing procedures. We also believe that its utility in traumatic brain injury can be substantial.”

The analyst explained his price target: “We see the primary valuation drivers at AEZS being based on both AEZS-108 (doxorubicin conjugate) and AEZS-130 (diagnostic). We project these revenues in our models. We use a 30% discount rate and triangulate FCFF, discounted EPS, and SOP models. Our model assumes dilution and uses a forecast share count for 2020. The equal weighted average of these metrics points to a $5.00 per share target.”
Biohero is offline   0 thumbs up / 1 thumbs down. Rate this post Yes | No Reply With Quote
Old 03-16-2015, 09:23 AM   Nav to Top  #4
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 298
Favorites: Aapl celg onxx
Rep Power: 116
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

Dilution (already closed) here created a fantastic buying opportunity for Gamblers . Big Phase 3 data for Endometrial Cancer coming in April this could push the sp significantly higher . AEZS is Trading below so the downside is very limited thats why the stock is very attractive for Gamblers .GL


Market Cap : $46 Million
Cash: ~ $65 Million
Price: $0.51


Maxim Maintains Buy On Aeterna Zentaris Ahead Of Zoptarelin-Dox Data
In a research report sent to investors today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Aeterna Zentaris (NASDAQ:AEZS) with a $2.00 price target, which implies an upside of 251% from current levels.
Kolbert said, “Zoptarelin-Dox data (interim analysis) in 1H15 represents a key event for the company. We believe that the incremental improvements to this standard of care agent should make it a low risk, high probability of positive outcome event.”

---------------
Zoptarelin Doxorubicin

–Potentially the first FDA approved medical therapy for treating
recurrent endometrial cancer

Interim results in H1-2015 (~128 events)

Significant Market Opportunity Potential

Estimated Potential Annual Market Value

Medical Therapy Treating Recurrent Endometrial Cancer

North America $300–$400 Million

Europe $150–$250 Million
Biohero is offline   Rate this post Yes | No Reply With Quote
Old 03-20-2015, 02:27 PM   Nav to Top  #5
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 298
Favorites: Aapl celg onxx
Rep Power: 116
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

Stock still trading wayy below cash . If the Phase 3 results are similar like those from Phase 2 then we will have here an 10 bagger easily .GL

Market Cap: $53 Million

Cash: $68 Million

Price: 0.59

from tuesdays conference call :

As you know we had, albeit small each of them, but two successful Phase 2 studies behind zoptarelin doxorubicin. In addition to endometrial cancer, we had one in ovarian cancer. Both trials, although conducted separately, demonstrated very favorable side effect profile, no reported cardio toxicity and they both also indicated overall survival of the 15 months compared to standard doxorubicin, the literature as you may recall is around seven to nine months, so it is very promising and we have a full plan of lifecycle management behind this compound based upon success in our current program in endometrial cancer we would then proceed into further indication development and working to really develop this molecule for applications making it a very important tool in the hands of oncologists and for their patients in a number of barriers in oncology

----

Results from a PII study in 43 patients with LHRH-positive advanced endometrial cancer were presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Patients received AEZS-108 267 mg/m2 by IV infusion over 2 hours, with retreatment every 3 weeks, for up to 6 courses. The primary endpoint was response rate based on RECIST criteria. 2 patients had a complete response (CR; 5.1%), 10 a partial response (PR; 25.6%), and 17 stable disease (SD; 43.6%), giving an Overall Response Rate (ORR = CR+PR) of 30.8 % and a Clinical Benefit Rate (CBR = CR+PR+SD) of 74.4%; responses were seen in patients who had prior platinum/taxane chemotherapy. Median time to progression and overall survival were 7 months and 14.3 months, respectively .
Biohero is offline   Rate this post Yes | No Reply With Quote
Old 03-26-2015, 12:50 PM   Nav to Top  #6
TheUnknowInvestor
Junior Trader
 
TheUnknowInvestor's Avatar
 
Join Date: Mar 2015
Location: Europe
Posts: 9
Favorites: It changes
Rep Power: 65
Reputation: 10
TheUnknowInvestor is on a distinguished road
Default

The reason your shares have lost 50% of their value since you started this topic is linked to the sudden surge of cash holdings.

The company issued nearly 60 million new shares generating $34.5 million, The company has no revenues from around $6 million in 2011.

Again this company is dying and dying fast they're issuing new shares to fund their ever growing deficit.

This company is not a safe investment.
__________________
www.againstthemarket.com
TheUnknowInvestor is offline   Rate this post Yes | No Reply With Quote
Reply

Similar Threads
Thread Thread Starter Forum Replies Last Post
Strong Buy: (BPAX) Mcap 71 M /Cash 70 M /FDA DECISION 14 FEB 2012 Biohero US Penny Stock Picks 1 01-02-2020 04:30 AM
Strong Buy: IGXT (MC $48 M) FDA DECISION ON FEBRUARY 3 =500%+ Potential !!! Biohero US Penny Stock Picks 34 04-10-2015 09:37 AM
Buy: TRL.TO (MC $83 M) FDA DECISION ON MAY 28 = 200% Potential !!!!! Biohero Canadian Stock Picks 0 05-20-2014 09:09 AM
Strong Buy: (NRI) Price: 0.065 // 3 Approved drugs + FDA decision on March 4 = 500%++ Potential Biohero Canadian Stock Picks 0 01-15-2013 10:05 AM
Strong Buy: (DND.T) FDA decision on 29 May /Mcap 24 M =1000% Potential ! Biohero Canadian Stock Picks 0 01-24-2012 08:02 AM


Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On